Metastatic colorectal cancer: markers to inform treatment selection

Molecular profiling metastatic colorectal cancer (mCRC) patients’ tumors have become a central aspect of a personalized therapy approach to treating mCRC.

Data from a recent retrospective subanalysis showed that patients with mCRC had different treatment outcomes based on the location of their tumor. Should physicians solely use the location of a mCRC patients’ tumor to inform treatment selection?

Leading medical oncologist Professor Claus-Henning Köhne discusses this in light of broader evidence on biomarkers in mCRC and current recommendations for patients.